[1] Park D, Sahai E, Rullan A.  SnapShot: cancer-associated fibroblasts[J]. Cell, 2020, 181(2): 486-486.e1.   doi: 10.1016/j.cell.2020.03.013
[2] Lebleu VS, Neilson EG.  Origin and functional heterogeneity of fibroblasts[J]. FASEB J, 2020, 34(3): 3519-3536.   doi: 10.1096/fj.201903188R
[3] Bu LK, Baba H, Yoshida N, et al.  Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment[J]. Oncogene, 2019, 38(25): 4887-4901.   doi: 10.1038/s41388-019-0765-y
[4] Scanlan MJ, Raj BK, Calvo B, et al.  Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers[J]. Proc Natl Acad Sci USA, 1994, 91(12): 5657-5661.   doi: 10.1073/pnas.91.12.5657
[5] Hamson EJ, Keane FM, Tholen S, et al.  Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy[J]. Proteomics Clin Appl, 2014, 8(5/6): 454-463.   doi: 10.1002/prca.201300095
[6] Loktev A, Lindner T, Burger EM, et al.  Development of fibroblast activation protein-targeted radiotracers with improved tumor retention[J]. J Nucl Med, 2019, 60(10): 1421-1429.   doi: 10.2967/jnumed.118.224469
[7] Loktev A, Lindner T, Mier W, et al.  A tumor-imaging method targeting cancer-associated fibroblasts[J]. J Nucl Med, 2018, 59(9): 1423-1429.   doi: 10.2967/jnumed.118.210435
[8] Lindner T, Loktev A, Altmann A, et al.  Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein[J]. J Nucl Med, 2018, 59(9): 1415-1422.   doi: 10.2967/jnumed.118.210443
[9] Welt S, Divgi CR, Scott AM, et al.  Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts[J]. J Clin Oncol, 1994, 12(6): 1193-1203.   doi: 10.1200/JCO.1994.12.6.1193
[10] Eager RM, Cunningham CC, Senzer N, et al.  Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer[J]. Clin Oncol, 2009, 21(6): 464-472.   doi: 10.1016/j.clon.2009.04.007
[11] Meyer C, Dahlbom M, Lindner T, et al.  Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients[J]. J Nucl Med, 2020, 61(8): 1171-1177.   doi: 10.2967/jnumed.119.236786
[12] Giesel FL, Adeberg S, Syed M, et al.  FAPI-74 PET/CT using either 18F-AlF or cold-Kit 68Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients[J]. J Nucl Med, 2021, 62(2): 201-207.   doi: 10.2967/jnumed.120.245084
[13] Kratochwil C, Flechsig P, Lindner T, et al.  68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer[J]. J Nucl Med, 2019, 60(6): 801-805.   doi: 10.2967/jnumed.119.227967
[14] Baum RP, Schuchardt C, Singh A, et al.  Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results[J]. J Nucl Med, 2022, 63(3): 415-423.   doi: 10.2967/jnumed.120.259192
[15] Watanabe S, Noma K, Ohara T, et al.  Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma[J]. Cancer Biol Ther, 2019, 20(9): 1234-1248.   doi: 10.1080/15384047.2019.1617566
[16] Xing J, Gong Q Y, Zou R F, et al.  A novel fibroblast activation protein-targeted near-infrared fluorescent off-on probe for cancer cell detection, in vitro and in vivo imaging[J]. J Mater Chem B, 2018, 6(10): 1449-1451.   doi: 10.1039/c7tb03303f
[17] Ke MR, Chen SF, Peng XH, et al.  A tumor-targeted activatable phthalocyanine-tetrapeptide-doxorubicin conjugate for synergistic chemo-photodynamic therapy[J]. Eur J Med Chem, 2017, 127: 200-209.   doi: 10.1016/j.ejmech.2016.12.056
[18] Ji TJ, Zhao Y, Wang J, et al.  Tumor fibroblast specific activation of a hybrid ferritin nanocage-based optical probe for tumor microenvironment imaging[J]. Small, 2013, 9(14): 2427-2431.   doi: 10.1002/smll.201300600
[19]

Moon ES, Elvas F, Vliegen G, et al. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators[J/OL]. EJNMMI Radiopharm Chem, 2020, 5(1): 19[2022-04-24]. https://ejnmmipharmchem.springeropen.com/articles/10.1186/s41181-020-00102-z. DOI: 10.1186/s41181-020-00102-z.
[20]

Moon ES, Van Rymenant Y, Battan S, et al. In vitro evaluation of the squaramide-conjugated fibroblast activation protein inhibitor-based agents AAZTA5. SA. FAPi and DOTA. SA. FAPi[J/OL]. Molecules, 2021, 26(12): 3482[2022-04-24]. https://www.mdpi.com/1420-3049/26/12/3482. DOI: 10.3390/molecules26123482.
[21] Toms J, Kogler J, Maschauer S, et al.  Targeting fibroblast activation protein: radiosynthesis and preclinical evaluation of an 18F-labeled FAP inhibitor[J]. J Nucl Med, 2020, 61(12): 1806-1813.   doi: 10.2967/jnumed.120.242958
[22] Lindner T, Altmann A, Krämer S, et al.  Design and development of 99mTc-Labeled FAPI tracers for SPECT imaging and 188Re therapy[J]. J Nucl Med, 2020, 61(10): 1507-1513.   doi: 10.2967/jnumed.119.239731
[23]

Moon ES, Ballal S, Yadav MP, et al. Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time[J/OL]. Am J Nucl Med Mol Imaging, 2021, 11(6): 476−491[2022-04-24]. https://pubmed.ncbi.nlm.nih.gov/35003886.
[24]

Ballal S, Yadav MP, Moon ES, et al. First-in-human results on the biodistribution, pharmacokinetics, and dosimetry of [177Lu]Lu-DOTA. SA. FAPi and [177Lu]Lu-DOTAGA. (SA. FAPi)2[J/OL]. Pharmaceuticals (Basel), 2021, 14(12): 1212[2022-04-24]. https://www.mdpi.com/1424-8247/14/12/1212. DOI: 10.3390/ph14121212.
[25] Kelly JM, Jeitner TM, Ponnala S, et al.  A trifunctional theranostic ligand targeting fibroblast activation protein-α (FAPα)[J]. Mol Imaging Biol, 2021, 23(5): 686-696.   doi: 10.1007/s11307-021-01593-1
[26] Xu MX, Zhang P, Ding J, et al.  Albumin binder-conjugated fibroblast activation protein inhibitor radiopharmaceuticals for cancer therapy[J]. J Nucl Med, 2022, 63(6): 952-958.   doi: 10.2967/jnumed.121.262533
[27]

Wen XJ, Xu PF, Shi MQ, et al. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics[J/OL]. Theranostics, 2022, 12(1): 422−433[2022-04-24]. https://www.thno.org/v12p0422.htm. DOI: 10.7150/thno.68182.
[28] Ji TJ, Zhao Y, Ding YP, et al.  Transformable peptide nanocarriers for expeditious drug release and effective cancer therapy via cancer-associated fibroblast activation[J]. Angew Chem Int Ed, 2016, 55(3): 1050-1055.   doi: 10.1002/anie.201506262
[29] Yu QW, Tang X, Zhao W, et al.  Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles[J]. Acta Biomater, 2021, 133: 244-256.   doi: 10.1016/j.actbio.2021.05.002
[30] Windisch P, Röhrich M, Regnery S, et al.  Fibroblast activation protein (FAP) specific PET for advanced target volume delineation in glioblastoma[J]. Radiother Oncol, 2020, 150: 159-163.   doi: 10.1016/j.radonc.2020.06.040
[31] Syed M, Flechsig P, Liermann J, et al.  Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers[J]. Eur J Nucl Med Mol Imaging, 2020, 47(12): 2836-2845.   doi: 10.1007/s00259-020-04859-y
[32] Koerber SA, Staudinger F, Kratochwil C, et al.  The role of 68Ga-FAPI PET/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience[J]. J Nucl Med, 2020, 61(9): 1331-1336.   doi: 10.2967/jnumed.119.237016
[33] Kessler L, Ferdinandus J, Hirmas N, et al.  68Ga-FAPI as a diagnostic tool in sarcoma: data from the 68Ga-FAPI PET prospective observational trial[J]. J Nucl Med, 2022, 63(1): 89-95.   doi: 10.2967/jnumed.121.262096
[34] Dendl K, Koerber SA, Finck R, et al.  68Ga-FAPI-PET/CT in patients with various gynecological malignancies[J]. Eur J Nucl Med Mol Imaging, 2021, 48(12): 4089-4100.   doi: 10.1007/s00259-021-05378-0
[35] Zhao L, Chen SY, Chen SJ, et al.  68Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer[J]. Radiother Oncol, 2021, 158: 55-61.   doi: 10.1016/j.radonc.2021.02.015
[36] Wang LJ, Tang GH, Hu KZ, et al.  Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the evaluation of advanced lung cancer[J]. Radiology, 2022, 303(1): 191-199.   doi: 10.1148/radiol.211424
[37] Wei YC, Cheng K, Fu Z, et al.  [18F]AlF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer[J]. Eur J Nucl Med Mol Imaging, 2022, 49(5): 1671-1681.   doi: 10.1007/s00259-021-05638-z
[38] Wen XY, He XP, Jiao F, et al.  Fibroblast activation protein-α-positive fibroblasts promote gastric cancer progression and resistance to immune checkpoint blockade[J]. Oncol Res, 2017, 25(4): 629-640.   doi: 10.3727/096504016X14768383625385
[39] Fan CL, Guo W, Su GQ, et al.  Widespread metastatic gastric signet-ring cell carcinoma shown by 68Ga-FAPI PET/CT[J]. Clin Nucl Med, 2021, 46(2): e78-e79.   doi: 10.1097/RLU.0000000000003245
[40] Lan LJ, Liu HX, Wang YW, et al.  The potential utility of [68Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG[J]. Eur J Nucl Med Mol Imaging, 2022, 49(3): 963-979.   doi: 10.1007/s00259-021-05522-w
[41] Guo W, Pang YZ, Yao LL, et al.  Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2021, 48(5): 1604-1617.   doi: 10.1007/s00259-020-05095-0
[42] Hussain A, Voisin V, Poon S, et al.  Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21[J]. J Exp Med, 2020, 217(8): e20191094-.   doi: 10.1084/jem.20191094
[43] Röhrich M, Naumann P, Giesel FL, et al.  Impact of 68Ga-FAPI PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas[J]. J Nucl Med, 2021, 62(6): 779-786.   doi: 10.2967/jnumed.120.253062
[44] Pang YZ, Zhao L, Shang QH, et al.  Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer[J]. Eur J Nucl Med Mol Imaging, 2022, 49(4): 1322-1337.   doi: 10.1007/s00259-021-05576-w
[45] Kessel K, Seifert R, Weckesser M, et al.  Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging[J]. Ann Nucl Med, 2022, 36(3): 293-301.   doi: 10.1007/s12149-021-01702-8
[46] Ballal S, Yadav MP, Moon ES, et al.  Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study[J]. Thyroid, 2022, 32(1): 65-77.   doi: 10.1089/thy.2021.0412
[47] Pang YZ, Wei JH, Shang QH, et al.  68Ga-fibroblast activation protein inhibitor, a promising radiopharmaceutical in PET/CT to detect the primary and metastatic lesions of chromophobe renal cell carcinoma[J]. Clin Nucl Med, 2021, 46(2): 177-179.   doi: 10.1097/RLU.0000000000003454
[48] Röhrich M, Syed M, Liew DP, et al.  68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas-Imaging analysis and histological validation[J]. Radiother Oncol, 2021, 160: 192-201.   doi: 10.1016/j.radonc.2021.04.016
[49] Farzipour S, Shaghaghi Z, Abbasi S, et al.  Recent achievements about targeted alpha therapy-based targeting vectors and chelating agents[J]. Anticancer Agents Med Chem, 2022, 22(8): 1496-1510.   doi: 10.2174/1871520621666210727120308
[50] Ma H, Li FZ, Shen GH, et al.  In vitro and in vivo evaluation of 211At-labeled fibroblast activation protein inhibitor for glioma treatment[J]. Bioorg Med Chem, 2022, 55: 116600-.   doi: 10.1016/j.bmc.2021.116600
[51] Mukkamala R, Lindeman SD, Kragness KA, et al.  Design and characterization of fibroblast activation protein targeted pan-cancer imaging agent for fluorescence-guided surgery of solid tumors[J]. J Mater Chem B, 2022, 10(12): 2038-2046.   doi: 10.1039/d1tb02651h
[52] Zheng JL, Lin KX, Zheng S, et al.  68Ga-FAPI and 18F-PET/CT images in intestinal tuberculosis[J]. Clin Nucl Med, 2022, 47(3): 239-240.   doi: 10.1097/RLU.0000000000003917
[53] Sun R, Huang ZW, Wei J, et al.  68Ga-FAPI and 18F-FDG PET/CT findings in a patient with pancreatic tuberculosis mimicking malignant tumor[J]. Clin Nucl Med, 2022, 47(5): 653-654.   doi: 10.1097/RLU.0000000000004099
[54] Alçın G, Tatar G, Şahin R, et al.  Peritoneal tuberculosis mimicking peritoneal carcinomatosis on 68Ga-FAPI-04 and 18F-FDG PET/CT[J]. Clin Nucl Med, 2022, 47(8): e557-e558.   doi: 10.1097/RLU.0000000000004174
[55] Deng Y, Wu JH, Xu CQ, et al.  Primary solitary tuberculosis in the hepatic round ligament detected by 68Ga-FAPI PET/CT[J]. Clin Nucl Med, 2022, 47(5): e414-e416.   doi: 10.1097/RLU.0000000000004122
[56] Tillmanns J, Hoffmann D, Habbaba Y, et al.  Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction[J]. J Mol Cell Cardiol, 2015, 87: 194-203.   doi: 10.1016/j.yjmcc.2015.08.016
[57] Schmidkonz C, Rauber S, Atzinger A, et al.  Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging[J]. Ann Rheum Dis, 2020, 79(11): 1485-1491.   doi: 10.1136/annrheumdis-2020-217408
[58] Laverman P, van der Geest T, Terry SYA, et al.  Immuno-PET and immuno-SPECT of rheumatoid arthritis with radiolabeled anti-fibroblast activation protein antibody correlates with severity of arthritis[J]. J Nucl Med, 2015, 56(5): 778-783.   doi: 10.2967/jnumed.114.152959